Metabolic profile and structure–activity relationship of resveratrol and its analogs in human bladder cancer cells

Purpose: Resveratrol (RV), a promising anti-cancer candidate, is limited in application for its poor bioavailability. However, the better bioavailability has been found in some RV derivatives. So in this paper, we explore the structure–activity relationship and the metabolic profiles of RV and its analogs (polydatin [PD], oxyresveratrol [ORV], acetylresveratrol [ARV]) in human bladder cancer T24 cells, and then evaluate their active forms and key chemical functional groups which may determine the fate of tumor cells. Methods: Drug sensitivity is evaluated by MTT assay, HE staining and flow cytometry analysis after T24 cells treated with RV, PD, ORV and ARV, respectively. Then the drug metabolites, in alive and dead T24 cells, also in T24 cell supernatant and lysates, are qualitatively and quantitatively analyzed by high-performance liquid chromatography, liquid chromatography coupled with tandem mass spectrum and high-resolution mass spectrometry technologies, respectively. Results: RV, ORV and ARV inhibit bladder cancer cells growth in a dose- and time-dependent manner, and exert the anti-tumor potency to T24 cells in order of ORV>ARV>RV>PD. Meanwhile, similar metabolic profiles of the above compounds are found not only in cell supernatant and lysate, but also in dead and alive T24 cells after drug treatment, and the main metabolites of RV, ORV and PD are their prototypes, but ARV is mainly metabolized to RV. Conclusion: The inhibitory potencies to T24 cells in the order of ORV>ARV>RV>PD are related to the structure and metabolism of RV and its analogs. Meanwhile, the number and position of free phenolic hydroxyl groups play a prominent role in antitumor activities. Therefore, protecting phenolic hydroxyl groups, and inhibiting drug metabolism to keep phenolic hydroxyl groups free would be the promising strategies to ensure the bioactivity of RV and its analogs, and thus to improve RV’s bioactivity and promote RV clinical translation.

[1]  Ying Yan,et al.  Lumbrokinase/paclitaxel nanoparticle complex: potential therapeutic applications in bladder cancer , 2018, International journal of nanomedicine.

[2]  L. Gliemann.  What are the chances that resveratrol will be the drug of tomorrow? , 2018, Pharmacological research.

[3]  M. Valentovic.  Evaluation of Resveratrol in Cancer Patients and Experimental Models. , 2018, Advances in cancer research.

[4]  Zhong Zhou,et al.  Therapeutic Versatility of Resveratrol Derivatives , 2017, Nutrients.

[5]  Xiaodong Ma,et al.  Differential sensitivities of bladder cancer cell lines to resveratol are unrelated to its metabolic profile , 2017, Oncotarget.

[6]  J. Viña,et al.  Properties of Resveratrol: In Vitro and In Vivo Studies about Metabolism, Bioavailability, and Biological Effects in Animal Models and Humans , 2015, Oxidative medicine and cellular longevity.

[7]  J. Smoliga,et al.  Enhancing the Delivery of Resveratrol in Humans: If Low Bioavailability is the Problem, What is the Solution? , 2014, Molecules.

[8]  Xiao-yan Chen,et al.  Short-Term Resveratrol Exposure Causes In Vitro and In Vivo Growth Inhibition and Apoptosis of Bladder Cancer Cells , 2014, PloS one.

[9]  Shabana I. Khan,et al.  Microbial metabolism. Part 14. Isolation and bioactivity evaluation of microbial metabolites of resveratrol , 2013, Natural product research.

[10]  Shengyong Zhang,et al.  Pharmacokinetics, tissue distribution and excretion study of resveratrol and its prodrug 3,5,4'-tri-O-acetylresveratrol in rats. , 2013, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[11]  S. Pizzo,et al.  In vitro and in vivo evaluation of resveratrol and 3,5-dihydroxy-4'-acetoxy-trans-stilbene in the treatment of human prostate carcinoma and melanoma. , 2013, The Journal of surgical research.

[12]  M. Urpi-Sardà,et al.  Pharmacokinetics of resveratrol metabolic profile in healthy humans after moderate consumption of red wine and grape extract tablets. , 2012, Pharmacological research.

[13]  A. Amri,et al.  Administration of resveratrol: What formulation solutions to bioavailability limitations? , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[14]  Xiao-yan Chen,et al.  Metabolic Patterns and Biotransformation Activities of Resveratrol in Human Glioblastoma Cells: Relevance with Therapeutic Efficacies , 2011, PloS one.

[15]  M. Lindstrom,et al.  Resveratrol metabolites do not elicit early pro-apoptotic mechanisms in neuroblastoma cells. , 2011, Journal of agricultural and food chemistry.

[16]  Q. Wang,et al.  Identification of metabolic pattern and bioactive form of resveratrol in human medulloblastoma cells. , 2010, Biochemical pharmacology.

[17]  Xiangyi Zheng,et al.  Resveratrol induces apoptosis and cell cycle arrest of human T24 bladder cancer cells in vitro and inhibits tumor growth in vivo , 2010, Cancer science.

[18]  J. Planas,et al.  Quantification of trans-resveratrol and its metabolites in rat plasma and tissues by HPLC. , 2010, Journal of pharmaceutical and biomedical analysis.

[19]  M. Miksits,et al.  Antitumor activity of resveratrol and its sulfated metabolites against human breast cancer cells. , 2009, Planta medica.

[20]  P. Ho,et al.  The Impact of Aqueous Solubility and Dose on the Pharmacokinetic Profiles of Resveratrol , 2008, Pharmaceutical Research.

[21]  G. Lu,et al.  Optimization and validation of a chromatographic method for the simultaneous quantification of six bioactive compounds in Rhizoma et Radix Polygoni Cuspidati , 2008, The Journal of pharmacy and pharmacology.

[22]  Ayman El-Kattan,et al.  Impact of physiological, physicochemical and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans. , 2007, Expert opinion on drug metabolism & toxicology.

[23]  Joseph A. Baur,et al.  Therapeutic potential of resveratrol: the in vivo evidence , 2006, Nature Reviews Drug Discovery.

[24]  C. Sinico,et al.  Host–Guest Interaction Study of Resveratrol With Natural and Modified Cyclodextrins , 2006 .

[25]  T. Szekeres,et al.  Antioxidant, prooxidant and cytotoxic activity of hydroxylated resveratrol analogues: structure-activity relationship. , 2005, Biochemical pharmacology.

[26]  T. Walle,et al.  HIGH ABSORPTION BUT VERY LOW BIOAVAILABILITY OF ORAL RESVERATROL IN HUMANS , 2004, Drug Metabolism and Disposition.

[27]  Youngsoo Kim,et al.  Oxyresveratrol and Hydroxystilbene Compounds , 2002, The Journal of Biological Chemistry.

[28]  G. Maga,et al.  Specific Structural Determinants Are Responsible for the Antioxidant Activity and the Cell Cycle Effects of Resveratrol* , 2001, The Journal of Biological Chemistry.

[29]  L. Barrier,et al.  Comparative study of radical scavenger and antioxidant properties of phenolic compounds from Vitis vinifera cell cultures using in vitro tests. , 1997, Life sciences.

[30]  Y. Kano,et al.  Pharmacological properties of traditional medicines. XXII. Pharmacokinetic study of mulberroside A and its metabolites in rat. , 1996, Biological & pharmaceutical bulletin.